Materials and methods

Patients and Tissues

Paraffin blocks from nine cases of SPT specimens were obtained from Surgical Pathology Archives of the University of Texas Medical Branch (Galveston, TX, USA), Harbor-UCLA Medical Center (Torrance, CA, USA), and Methodist Hospital (Houston, TX, USA). Sections were stained with hematoxylin and eosin to confirm the presence of SPT on the paraffin blocks subjected to the study. These cases are listed in Table 1.

Table 1 - The patient characteristics of nine SPT cases.

Full table

The patients' characteristics are as follows: median age 38 (range 10–49 years), both male and female, mean tumor size 5.9 cm (range 3.2–12.8 cm). The location of tumor in pancreas: three at head, one at body, and five at tail. Eight of the nine tumors are confined within pancreas. No lymph node involvement in any of the tumors.

Immunohistochemistry

Immunohistochemical stains with E-cadherin (Zymed, San Francisco, CA, USA; 1:200) and -catenin (Dako, Glostrup, Denmark; 1:100) were performed in these nine cases. Count staining was performed using hematoxylin.

Genetic Analysis

SPT and surrounding normal pancreatic glandular tissue were first deparaffinized; DNA was then isolated by standard technique.¹⁴ -Catenin-specific primers were used to amplify the -catenin gene exon II. Primer sequences: forward 5'-AGC TGA TTT GAT GGA GTT GG-3'; reverse 5'-ACC AGC TAC TTG TTC TTG AG-3'. The PCR products were sequenced and compared with wild-type -catenin gene in GenBank (AY081165).

Results

As shown in Figure 1, hematoxylin and eosin stained slides of all nine tumors show similar classic microscopic features of SPT: solid and pseudopapillary tumor pattern (Figure 1). The solid area was surrounded by pseudo-papillary area.

Figure 1.

Hematoxylin and eosin staining of specimens from solid pseudopapillary tumor of pancreas ( 400). (a) Case 1 solid area; (b) case 1 pseudopapillary area.

Full figure and legend (224K)

To test whether cell adhesion is altered in SPT, we examined expression of E-cadherin and -catenin by immunohistochemistry. As shown in Figure 2, all the tumors, regardless of 'solid' or 'pseudopapillary' regions, were negative for E-cadherin staining; whereas the surrounding glandular cells are positive. In contrast, nuclear localization of -catenin is detected in both 'solid' and 'pseudo-papillary' regions (Figure 3). Expression of these cell adhesion molecules is altered in SPT, which can be used to differentiate tumor tissues from the surrounding normal pancreas.

Figure 2.

Immunohistochemistry detection of E-cadherin in SPT specimens ( 400); (a) case 1 solid area; (b) case 1 pseudopapillary area; (c) case 1 normal duodenal gland. Positive staining is in red. Count staining was performed using hematoxylin.

Full figure and legend (320K)

Figure 3.

Immunohistochemistry detection of -catenin in SPT specimens ( 400); (a) case 1 solid area; (b) case 1 pseudopapillary area. Positive staining was in red and count staining was performed using hematoxylin.

Full figure and legend (196K)

To test whether gene mutation of -catenin is responsible for nuclear localization of the protein, we examined the exon III of the -catenin gene from Case 2 SPT tumor cells. Sequencing the genomic DNAs extracted from deparaffinized tissue revealed a single base pair change (S33C), which is located in a GSK-3- phosphorylation site (Figure 4).^{15, 16, 17} This finding is consistent with previous literature reports that -catenin mutations occur commonly in this type of tumor.

Figure 4.

Mutation analysis of -catenin in the tumor-S33C mutation. Genomic DNAs from paraffin-embedded tissues were purified using a procedure reported previously,¹⁴ and the exon III genomic DNA of the -catenin was amplified by PCR as reported primers (21). Alteration of -catenin was detected by direct sequencing of the PCR product in our core facility. The mutation of C to G was indicated by an arrow, which results in a missense mutation of Ser35 to Cys35 as predicted from GenBank AY081165 and GenPept AAL89457. Only the sequence encoding amino acids 24–36 was shown. The mutation was confirmed by two independent experiments.

Full figure and legend (118K)

These results indicate that loss of adhesion molecule complexes is an important feature of SPT, and may be useful for future clinical diagnosis of this tumor type.

Discussion

Since it was first described in 1959, the origin and pathogenesis of SPT have been controversial. Mutations of the -catenin gene have been identified in most cases of SPTs.¹⁰ The mutations are mostly at or around the GSK-3- phosphorylation sites. It has been postulated that these somatic mutations would interfere with normal phosphorylation by GSK-3- and the subsequent ubiquitin-mediated degradation of the -catenin protein. This is consistent with the fact that strong nuclear and cytoplasmic accumulation of -catenin protein is present in nearly all SPTs, and that cyclin D1, a downstream transcriptional target of the nuclear -catenin-Tcf/Lef complex, is overexpressed in SPTs. In our study, the -catenin gene from SPT contains a somatic mutation, which changes from serine to cysteine. This S33C mutation has been identified in -catenin genes of various tumors^{15, 18, 19, 20} and this serine has been shown to be mutated in other SPTs.¹⁰ On the basis of these findings, it is suggested that the Wnt signaling is associated with -catenin mutations and may play an important role in tumorigenesis of SPT.¹⁰ However, this hypothesis fails to explain the characteristic microscopic 'solid' and 'pseudopapillary' features in SPT.

It has been well known that -catenin protein is an important linking molecule between E-cadherin and the cytoskeleton. Our immunohistochemical staining of E-cadherin and -catenin suggest that nuclear localization of -catenin as well as E-cadherin loss are important changes in this type of tumor. Although it is known that -catenin mutation can cause disorganization of E-cadherin, silencing of E-cadherin by a variety of factors has been reported in several types of tumors. On the basis of these data, we propose that disruption of adhesion junction is the major feature for SPT. Whereas nuclear translocation is caused by -catenin mutation, loss of E-cadherin expression can result from promoter silencing, overexpression of transcription repressors such as Snail. As a result of adhesion junction disruption, the pseudopapillary portion of the tumor is formed with help of other factors, such as mechanic stress. Figure 5 shows our proposed model for morphological development of SPT.

Figure 5.

A model for development of SPT. Loss of adhesion junction is an important feature of SPT through silencing of E-cadherin expression and nuclear translocation of -catenin after activating mutations. Mutation of -catenin can also disrupt E-cadherin localization. In the absence of adhesion junction, other factors can promote morphological changes of SPT to be either 'solid' or 'pseudopapillary'.

Full figure and legend (18K)

In conclusion, our results suggest that loss of adhesion junction is a unique microscopic feature distinguishing the SPT tumor from the normal pancreas. Our findings suggest that loss of cytoplasmic -catenin protein in the cell adhesion complex due to -catenin gene mutation results in instability of the complex, loss of E-cadherin in cell membrane, and eventually dissociation of the tumor cells to form the pseudopapillary pattern.

References

1. Frantz VK. Tumors of the pancreas. In: Atlas of Tumor Pathology, Vol. 7. Armed Forces Institute of Pathology: Washington, DC, 1959, pp 32–33.
2. Kloppel G, Luttges J, Klimstra DS, et al. Solidpseudopapillary Neoplasm. IARC Press: Lyon, France, 2000, pp 473–480.
3. Solcia E, Capella C, Kloppel G. Tumors of the pancreas. In: Atlas of Tumor Pathology, 3rd series. Armed Forces Institute of Pathology: Washington, DC, 1997, pp 120–130.
4. Klimstra DS, Wenig BM, Heffess CS. Solid-pseudopapillary tumor of the pancreas: a typically cystic carcinoma of low malignant potential. Semin Diagn Pathol 2000;17:66–80. | PubMed | ISI | ChemPort |
5. Papavramidis T, Papavramidis S. Solid pseudopapillary tumors of the pancreas: review of 718 patients reported in English literature. J Am Coll Surg 2005;200:965–972. | Article | PubMed |
6. Pettinato G, Manivel JC, Ravetto C, et al. Papillary cystic tumor of the pancreas. A clinicopathologic study of 20 cases with cytologic, immunohistochemical, ultrastructural, and flow cytometric observations, and a review of the literature. Am J Clin Pathol 1992;98:478–488. | PubMed | ISI | ChemPort |
7. Yamaguchi K, Tanaka M. Radiologic imagings of cystic neoplasms of the pancreas. Pancreatology 2001;1:633–636. | Article | PubMed | ChemPort |
8. Kosmahl M, Seada LS, Janig U, et al. Solid-pseudopapillary tumor of the pancreas: its origin revisited. Virchows Arch 2000;436:473–480. | Article | PubMed | ChemPort |
9. Tiemann K, Kosmahl M, Ohlendorf J, et al. Solid pseudopapillary neoplasms of the pancreas are associated with FLI-1 expression, but not with EWS/FLI-1 translocation. Mod Pathol 2006;19:1409–1413. | PubMed | ChemPort |
10. Abraham SC, Klimstra DS, Wilentz RE, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor -catenin mutations. Am J Pathol 2002;160:1361–1369. | PubMed | ISI | ChemPort |
11. Tanaka Y, Kato K, Notohara K, et al. Frequent -catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. Cancer Res 2001;61:8401–8404. | PubMed | ISI | ChemPort |
12. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002;62:1613–1618. | PubMed | ISI | ChemPort |
13. Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 1996;61:514–523. | Article | PubMed | ISI | ChemPort |
14. Sheng T, Li C, Zhang X, et al. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer 2004;3:29. | Article | PubMed | ChemPort |
15. Chan EF, Gat U, McNiff JM, et al. A common human skin tumour is caused by activating mutations in -catenin. Nat Genet 1999;21:410–413. | Article | PubMed | ISI | ChemPort |
16. Orford K, Crockett C, Jensen JP, et al. Serine phosphorylation-regulated ubiquitination and degradation of -catenin. J Biol Chem 1997;272:24735–24738. | Article | PubMed | ISI | ChemPort |
17. Liu C, Li Y, Semenov M, et al. Control of -catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002;108:837–847. | Article | PubMed | ISI | ChemPort |
18. Mirabelli-Primdahl L, Gryfe R, Kim H, et al. -catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999;59:3346–3351. | PubMed | ISI | ChemPort |
19. Wright K, Wilson P, Morland S, et al. -catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer 1999;82:625–629. | Article | PubMed | ISI | ChemPort |
20. Gamallo C, Palacios J, Moreno G, et al. -catenin expression pattern in stage I and II ovarian carcinomas: relationship with -catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999;155:527–536. | PubMed | ISI | ChemPort |

Acknowledgements

Grant numbers and sources of support: NCI R01-94160 (Xie, J), Sealy Center for Cancer Cell Biology Predoctoral fellowship (Stelter, AA) and NASA scholarship (Stelter, AA).